Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Tetraphase Pharmaceu (TTPH)

Tetraphase Pharmaceu (TTPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,764
  • Shares Outstanding, K 2,716
  • Annual Sales, $ 18,900 K
  • Annual Income, $ -72,160 K
  • 60-Month Beta 2.46
  • Price/Sales 0.65
  • Price/Cash Flow N/A
  • Price/Book 0.29

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -7.20
  • Number of Estimates 1
  • High Estimate -7.20
  • Low Estimate -7.20
  • Prior Year -7.40
  • Growth Rate Est. (year over year) +2.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.36 +48.69%
on 10/09/19
7.00 -28.69%
on 09/19/19
-1.54 (-23.54%)
since 09/17/19
3-Month
3.36 +48.69%
on 10/09/19
8.80 -43.30%
on 07/22/19
-3.48 (-41.09%)
since 07/17/19
52-Week
3.36 +48.69%
on 10/09/19
49.60 -89.94%
on 10/19/18
-43.61 (-89.73%)
since 10/17/18

Most Recent Stories

More News
SmarTrend Watching for Potential Rebound in Shares of Tetraphase Pharm After 2.17% Loss

Tetraphase Pharm (NASDAQ:TTPH) traded in a range yesterday that spanned from a low of $3.38 to a high of $3.71. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $3.55...

TTPH : 4.97 (+5.74%)
SmarTrend Watching for Potential Rebound in Shares of Tetraphase Pharm After 2.44% Loss

Tetraphase Pharm (NASDAQ:TTPH) traded in a range yesterday that spanned from a low of $3.82 to a high of $4.27. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $4.02...

TTPH : 4.97 (+5.74%)
Tetraphase Pharmaceuticals Announces Reverse Stock Split

Tetraphase Pharmaceuticals, Inc. (Nasdaq: TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA(TM) (eravacycline for injection) to treat serious and life-threatening...

TTPH : 4.97 (+5.74%)
Tetraphase Pharmaceuticals to Present XERAVA(TM) (Eravacycline) Data at IDWeek 2019

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA(TM) (eravacycline for injection) to treat serious and life-threatening...

TTPH : 4.97 (+5.74%)
Tetraphase Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA(TM) (eravacycline for injection) to treat serious and life-threatening...

TTPH : 4.97 (+5.74%)
Watch for Tetraphase Pharm to Potentially Rebound After Falling 1.41% Yesterday

Tetraphase Pharm (NASDAQ:TTPH) traded in a range yesterday that spanned from a low of $0.24 to a high of $0.27. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $0.25...

TTPH : 4.97 (+5.74%)
Tetraphase Pharmaceuticals (TTPH) Reports Q2 Loss, Lags Revenue Estimates

Tetraphase (TTPH) delivered earnings and revenue surprises of -10.53% and -49.62%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

TTPH : 4.97 (+5.74%)
Tetraphase: 2Q Earnings Snapshot

WATERTOWN, Mass. (AP) _ Tetraphase Pharmaceuticals Inc. (TTPH) on Thursday reported a loss of $22.9 million in its second quarter.

TTPH : 4.97 (+5.74%)
Tetraphase Pharmaceuticals Reports Second Quarter 2019 Financial Results and Highlights Recent Corporate Developments

--Increased Formulary Uptake, with a 99.7% Success Rate for all Formulary Reviews to Date

TTPH : 4.97 (+5.74%)
Tetraphase Pharmaceuticals to Host Second Quarter 2019 Financial Results Conference Call

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing novel tetracyclines to treat serious and life-threatening conditions, today announced that company...

TTPH : 4.97 (+5.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade TTPH with:

Business Summary

Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug...

See More

Key Turning Points

2nd Resistance Point 5.21
1st Resistance Point 4.96
Last Price 4.97
1st Support Level 4.30
2nd Support Level 3.89

See More

52-Week High 49.60
Fibonacci 61.8% 31.93
Fibonacci 50% 26.48
Fibonacci 38.2% 21.02
Last Price 4.97
52-Week Low 3.36

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar